Potassium Overdose in Patient with Chronic Kidney Disease on Losartan: A Case Report. [PDF]
Naseem A +4 more
europepmc +1 more source
Comprehensive analysis of heart failure: Characteristics, treatment, and outcomes in a reduced ejection fraction patient cohort from SIDIAP, Catalonia, Spain. [PDF]
Giner-Soriano M +5 more
europepmc +1 more source
Clinical Outcomes Associated With In-Hospital Versus Delayed Outpatient Initiation of Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. [PDF]
Oletu H +8 more
europepmc +1 more source
Causal effects of drug exposure on gastric cancer risk: a Mendelian randomization study involving 23 commonly used medications in the European population. [PDF]
Zhang G +5 more
europepmc +1 more source
Joint analysis of hemoglobin-to-RDW and creatinine-to-albumin ratios for mortality prediction in critical heart failure. [PDF]
Chen S +9 more
europepmc +1 more source
Acquired Angioedema-A Challenge in Medical Practice: A Narrative Review. [PDF]
Poznańska-Kurowska K +4 more
europepmc +1 more source
Angiotensin IV receptors and signaling in opossum kidney cells
The pharmacological properties and signaling of angiotensin IV (ANG IV) receptors were studied in opossum kidney cell line OK7A. Saturation binding experiments with 125I-labeled ANG IV demonstrated the presence of high-affinity ANG IV binding sites in OK7A cell membranes with a dissociation constant (Kd) of 0.40 +/- 0.08 nM and a maximal amount of ...
N, Dulin +5 more
openaire +3 more sources
Angiotensin IV (Ang IV) is a hexapeptide fragment corresponding to amino acids 3–8 (VYIHPF) of angiotensin II (Ang II) that is formed by consecutive actions of aminopeptidase A and aminopeptidase N (1) (Fig. 1). Ang IV acts as a weak agonist at the Ang II AT1 receptor, and was generally believed to have no physiological role because of its ...
T. A. Jenkins +3 more
openaire +2 more sources

